Chelsea Therapeutics International Ltd. (NASDAQ:CHTP)

CAPS Rating: 2 out of 5

A development stage pharmaceutical company that seeks to acquire and develop innovative products for the treatment of a variety of human diseases.

Recs

1
Player Avatar zzlangerhans (99.82) Submitted: 9/23/2011 6:14:20 PM : Outperform Start Price: $3.92 CHTP Score: -30.16

CAPS gypped me out of my sub-4 Chelsea pick last month so I closed it for a positive score, knowing market volatility would give me another opportunity. I expect Chelsea to submit the NDA for Northera for neurogenic orthostatic hypotension in the near future. The company has stated they anticipate a six month priority review, which would indicate a PDUFA in March or April of 2012. Meanwhile, interim efficacy data from the phase II trial of CH-4051 is also expected very shortly, and I expect this to be positive based on phase II data from predecessor anti-folate CH-1504 from March 2009. Northera is also in trials for other diverse indications such as Parkinsonian orthostatic hypotension and ADHD.

Featured Broker Partners


Advertisement